Key takeaways:
- A federal judge in Texas issued a stay on the FDA’s approval of mifepristone, a drug widely used for medication abortions.
- The Department of Justice (DOJ) has filed an appeal and is seeking an immediate stay of the decision.
- The ruling has been met with criticism from abortion rights advocates and organizations such as the ACLU, and could have a significant impact on access to abortion services in the United States.
On Friday, a federal judge in Texas issued a stay on the Food and Drug Administration’s (FDA) approval of mifepristone, a drug widely used for medication abortions. This decision affects blue states with robust abortion protections, as well as the rest of the country.
In response, U.S. Attorney General Merrick Garland said in a statement that the Department of Justice (DOJ) “strongly disagrees with the decision” and “will be appealing the court’s decision and seeking a stay pending appeal.” The DOJ has already filed an appeal and is seeking an immediate stay of the decision.
President Joe Biden also released a statement in response to the ruling, saying, “My Administration will fight this ruling.” He added that the decision “is a direct challenge to Roe v. Wade, which is settled law and a matter of settled precedent.”
The ruling has been met with criticism from abortion rights advocates, who argue that it is an attempt to limit access to abortion services. The American Civil Liberties Union (ACLU) has already filed a motion to intervene in the case, and other organizations are expected to follow suit.
The implications of this ruling are far-reaching and could have a significant impact on access to abortion services in the United States. The outcome of the DOJ’s appeal will be closely watched, as it could set a precedent for future cases.
Be First to Comment